SERA PROGNOSTICS, INC.SERAEarnings & Financial Report
Sera Prognostics, Inc. is a women's health diagnostics company dedicated to developing and commercializing evidence-based clinical tests to improve pregnancy and neonatal health outcomes. Its core products include precision preterm birth risk assessment tests, serving healthcare providers, maternal health partners and patients mainly across the United States.
Revenue
$38.0K
Gross Profit
$-2.0K
Operating Profit
$-9.3M
Net Profit
$-8.2M
Gross Margin
-5.3%
Operating Margin
-24342.1%
Net Margin
-21544.7%
YoY Growth
N/A
EPS
$-0.20
SERA PROGNOSTICS, INC. Q1 FY2025 Financial Summary
SERA PROGNOSTICS, INC. reported revenue of $38.0K for Q1 FY2025, with a net profit of $-8.2M (down 1.1% YoY) (-21544.7% margin). Cost of goods sold was $40.0K, operating expenses totaled $9.2M.
Key Financial Metrics
| Total Revenue | $38.0K |
|---|---|
| Net Profit | $-8.2M |
| Gross Margin | -5.3% |
| Operating Margin | -24342.1% |
| Report Period | Q1 FY2025 |
SERA PROGNOSTICS, INC. Annual Revenue by Year
SERA PROGNOSTICS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $77.0K).
| Year | Annual Revenue |
|---|---|
| 2024 | $77.0K |
| 2023 | $306.0K |
| 2022 | $268.0K |
SERA PROGNOSTICS, INC. Quarterly Revenue & Net Profit History
SERA PROGNOSTICS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $16.0K | -44.8% | $-7.8M | -48837.5% |
| Q2 FY2025 | $17.0K | -29.2% | $-8.0M | -47329.4% |
| Q1 FY2025 | $38.0K | — | $-8.2M | -21544.7% |
| Q4 FY2024 | $24.0K | -41.5% | $-8.6M | -35745.8% |
| Q3 FY2024 | $29.0K | -31.0% | $-7.9M | -27306.9% |
| Q2 FY2024 | $24.0K | -80.5% | $-8.3M | -34595.8% |
| Q1 FY2024 | $0 | — | $-8.1M | N/A |
| Q4 FY2023 | $41.0K | -36.9% | $-7.9M | -19329.3% |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $41000 | $0 | $24000 | $29000 | $24000 | $38000 | $17000 | $16000 |
| YoY Growth | -36.9% | N/A | -80.5% | -31.0% | -41.5% | N/A | -29.2% | -44.8% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $95.4M | $89.9M | $84.9M | $79.0M | $72.6M | $118.2M | $111.8M | $108.1M |
| Liabilities | $25.3M | $25.1M | $25.1M | $24.4M | $24.8M | $23.4M | $23.6M | $25.9M |
| Equity | $70.2M | $64.8M | $59.8M | $54.7M | $47.8M | $94.8M | $88.2M | $82.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-6.8M | $5.0M | $-5.9M | $-7.0M | $-6.3M | $-7.6M | $-5.5M | $-6.5M |